Pharvaris is a cash-burning clinical-stage biotech with a quality score of only 1.5 out of 10, but strong analyst conviction with 48% upside to targets and a momentum breakout pattern — the risk profile is speculative with 3 of the last 4 earnings misses.
Thesis pillars
- Quality Floor Breach Cash Burn→Stable
- Earnings Miss Pattern→Stable
- Analyst Conviction Upside→Stable
- +1 more pillar — see the Why tab for full reasoning
Pharvaris N.V. (PHVS) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $33.22: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 2.2:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin... Read more
Sell if holding. Engine safety override at $33.22: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 2.2:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.1/10, moderate confidence.
Passes 6/8 gates (positive momentum, favorable risk/reward ratio, no SEC red flags, earnings proximity 38d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Recent developments
updated 2026-07-07Recent Developments — Pharvaris N.V.
Latest news
- NEWS Pharvaris Says FDA Accepts NDA For Deucrictibant IR Capsule (20 Mg) For On-Demand Treatment Of Hereditary Angioedema Att — benzinga Jul 6, 2026 positive
- NEWS Morgan Stanley Maintains Overweight on Pharvaris, Raises Price Target to $46 — benzinga Jun 25, 2026 positive
- NEWS Pharvaris Highlights New Deucrictibant Data at EAACI 2026, Says HAE Treatment Data Support On-Demand and Preventive Use — benzinga Jun 15, 2026 positive
- NEWS Pharvaris To Present Oral And Poster Data On Oral Deucrictibant At EAACI Annual Congress 2026 — benzinga May 29, 2026 positive
- NEWS Citizens Maintains Market Outperform on Pharvaris, Lowers Price Target to $74 — benzinga May 13, 2026 positive
Generated 2026-07-07T12:21:43Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $33.22: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 2.2:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $30.89. Score 5.1/10, moderate confidence.
Take-profit target: $40.38 (+21.6% upside). Prior stop was $30.89. Stop-loss: $30.89.
Quality below floor (1.5 < 4.0).
Pharvaris N.V. trades at a P/E of N/A (forward -12.8). TrendMatrix value score: 7.5/10. Verdict: Sell.
20 analysts cover PHVS with a consensus score of 4.3/5. Average price target: $46.
What does Pharvaris N.V. do?Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies...
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.